Journal of Pain Research (May 2021)
Repeat Epidural Injections of SP-102 (Dexamethasone Sodium Phosphate Injectable Gel) in Subjects with Lumbosacral Radiculopathy
Abstract
Richard Radnovich,1 Jill Heinz,1 Chris Ambrose,2 Elizabeth Stannard,2 Dmitri Lissin2 1Injury Care Research, Boise, ID, USA; 2Global Research and Development, Scilex Pharmaceuticals Inc, Palo Alto, CA, USACorrespondence: Dmitri LissinScilex Pharmaceuticals Inc, 960 San Antonio Road, Palo Alto, CA, 94306, USA, Tel +1 650-430-3238Email [email protected]: SP-102 is a novel epidural steroid injection (ESI) formulation of 10 mg dexamethasone sodium phosphate in a viscous gel solution. Repeat dosing of ESIs is possible if required for pain relief, but with consideration of hypothalamic–pituitary–adrenal (HPA) axis suppression from prolonged systemic exposure. This phase I/II study investigated the effect of initial and repeat SP-102 injections on HPA suppression and analgesia.Methods: Subjects with lumbosacral radiculopathy received an initial epidural SP-102 injection (T1) on day 1, followed by a repeat injection (T2) on ≥ 28 days later. To determine HPA suppression, area under the effect curve over 28 days and maximum change from baseline were calculated for cortisol, glucose levels, and white blood cell (WBC) count. Equivalent effect on HPA suppression of T1 relative to T2 was determined if the 90% CIs for ratios of these measures were within 80%– 125%. The effect of repeat injections on leg and back pain was also assessed.Results: Based on the responder analysis, all subjects had achieved a cortisol response by day 3 after initial injection and by day 2 after repeat injection. The repeat injection had similar effects on glucose levels and WBC count to the initial injection. Pain scores decreased after each injection and remained low for the 28-day follow-up, with some evidence of improved analgesic effect of the second dose compared with the first. There were no serious adverse events or discontinuations due to adverse events.Conclusion: The lack of cumulative effect and rapid resolution of HPA suppression following repeated SP-102 dosing suggests that consideration of HPA pharmacodynamics is not clinically relevant when making decisions regarding repeat dosing. SP-102 ESIs provided prolonged pain relief, with preliminary evidence of greater efficacy after repeat injection. A phase III trial is ongoing.Clinical Trial Identifier: ClinicalTrials.gov: NCT03613662.Keywords: epidural steroid injections, lubosacral radicuar pain, sciatica, neuropathic pain
